Sun Pharma surges 3%. 3 reasons why Motilal Oswal has ‘Buy’ rating
- Posted on March 11, 2025
- By Financial Express
- 2 Views
Sun Pharma surges 3%. 3 reasons why Motilal Oswal has ‘Buy’ rating
Sun Pharma surges 3% on Checkpoint Therapeutics acquisition; Motilal Oswal maintains 'Buy' with 22% upside potential. Read more!
